


PERSPECTIVES

# Capillary Inward-Rectifying K<sup>+</sup> Crippled in a Mouse Model of Alzheimer's Disease: Phosphatidylinositol 4,5-Bisphosphate to the Rescue!

William F. Jackson  \*

Department of Pharmacology & Toxicology, College of Osteopathic Medicine, Michigan State University, East Lansing, MI 48824, USA

\*Address correspondence to W.F.J. (e-mail: jacks783@msu.edu)

## A Perspective on: "PIP<sub>2</sub> Improves Cerebral Blood Flow in a Mouse Model of Alzheimer's Disease"

Blood flow to the brain is precisely regulated to match the metabolic activity of neurons.<sup>1</sup> This process, dubbed neurovascular coupling, ensures the appropriate supply of oxygen, glucose, and other substrates necessary for proper brain function.<sup>1</sup> It has become apparent over the past two decades that cerebral blood flow is reduced, and neurovascular coupling is attenuated in a number of brain pathologies, including Alzheimer's disease (AD).<sup>1-3</sup> However, the time course of dysregulation of cerebral blood flow relative to the onset of cognitive impairment, the underlying mechanisms responsible for the dysregulation of blood flow, and, importantly, if reversal of impaired cerebrovascular function improves cognition in AD remains in question. Mughal et al.<sup>4</sup> in this issue of *Function* provide compelling evidence that reduced membrane phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>), an established characteristic of Alzheimer's pathology,<sup>5</sup> inactivates brain capillary endothelial cell (EC) inward-rectifying K<sup>+</sup> (K<sub>IR</sub>2.1) channels, resulting in attenuated neurovascular coupling in the whisker barrel cortex in a murine model of AD in which the mice express five mutant human genes associated with familial AD: three amyloid precursor protein (APP) genes (APP<sup>swe</sup>, APP<sup>fl</sup>, and APP<sup>lon</sup>) and two presenilin 1 (PS1 and PSEN1) genes (PSEN1 M146L and PSEN1 L286V; 5XFAD mouse).<sup>6</sup> The authors demonstrate that capillary EC K<sub>IR</sub>2.1 channel function is crippled in this model system and that application of a

PIP<sub>2</sub> analog in patch-clamp experiments completely rescues the channel function. Importantly, they go on to show that K<sup>+</sup>-induced enhancement of red blood cell flux in capillaries, an in vivo test of capillary EC K<sub>IR</sub>2.1 function, and neurovascular coupling in the somatosensory cortex invoked by whisker stimulation are likewise impaired in the 5XFAD mouse model of AD. Most excitingly, Mughal et al.<sup>4</sup> demonstrated rescue of capillary EC K<sub>IR</sub>2.1 function and neurovascular coupling by intravenous (IV) administration of a PIP<sub>2</sub>-analog. These data offer hope of dietary or pharmacological restoration of capillary EC membrane PIP<sub>2</sub> levels and restoration of ion channel function impaired by a reduction in PIP<sub>2</sub> in AD. The authors' findings also strongly support this group's contention that capillary EC K<sub>IR</sub>2.1 channels serve as an important vascular sensor of extracellular [K<sup>+</sup>] released in proportion to neural and glial activity, providing a key signal that couples increases in local neuron electrical activity with increases in capillary blood flow to these active cells.

Several questions remain to be answered. First, what is the time course of capillary EC PIP<sub>2</sub> depletion relative to loss of neurons and, importantly, impaired cognitive function? How early are the capillary K<sub>IR</sub>2.1 channels crippled in the progression of AD? Mughal et al.<sup>4</sup> used 12-month-old 5XFAD mice in their investigations. However, studies in this model have shown impaired cognition and loss of neurons as early as 4-5 months, while changes in cerebral blood flow appear at approximately 7 months.<sup>7</sup> Is capillary EC K<sub>IR</sub>2.1 function also impaired at these time points? Second, does recovery of K<sub>IR</sub>2.1 function by addition of exogenous PIP<sub>2</sub> restore or improve cognitive function in

Submitted: 20 March 2021; Revised: 22 March 2021; Accepted: 22 March 2021

© The Author(s) 2021. Published by Oxford University Press on behalf of American Physiological Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

this model of AD and at what point does the PIP<sub>2</sub> have to be administered? Third, how selective was the IV administration of the PIP<sub>2</sub> analog to capillary EC? Decreased membrane PIP<sub>2</sub> also has been implicated in reduced synaptic transmission in AD models.<sup>5,8</sup> Did the IV administration of the PIP<sub>2</sub> analog improve signaling elsewhere in the neurovascular unit (neurons, astrocytes, etc.)? Fourth, while capillary EC K<sub>IR</sub>2.1 function is impaired by loss of PIP<sub>2</sub>,<sup>4,9</sup> capillary EC TRPV<sub>4</sub> function should be enhanced by loss of PIP<sub>2</sub>.<sup>9</sup> Does this imply that an increase in capillary EC TRPV<sub>4</sub> activity may contribute, somehow, to impaired neurovascular coupling in AD? Finally, it will be interesting to see if capillary K<sub>IR</sub>2.1 is also crippled in human AD and whether K<sub>IR</sub>2.1 function can be restored by PIP<sub>2</sub> supplementation. Obviously, additional research will be required to answer these and other questions that arise from this provocative study. Nonetheless, the paper by Mughal et al.<sup>4</sup> provides exciting new information that may help in our fight to combat cerebral pathologies, like AD.

## Funding

Supported by National Heart, Lung and Blood Institute grants HL-137694 and PO1-HL-070687.

## Conflict of interest statement

No conflicts of interest, financial or otherwise, are declared by the author. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

## References

1. Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. *Neuron* 2017;96(1):17–42.
2. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. *Nat Rev Neurosci* 2017;18(7):419–434.
3. Iadecola C, Gottesman RF. Cerebrovascular alterations in Alzheimer disease. *Circ Res* 2018;123(4):406–408.
4. Mughal A, Harraz OF, Gonzales AL, Hill-Eubanks D, Nelson MT. PIP<sub>2</sub> improves cerebral blood flow in a mouse model of Alzheimer's disease. *Function* 2021;2(2). doi: 10.1093/function/zqab010.
5. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. *Nat Rev Neurosci* 2011;12(5):284–296.
6. Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J Neurosci* 2006;26(40):10129–10140.
7. Igarashi H, Ueki S, Kitaura H, et al. Longitudinal GluCEST MRI changes and cerebral blood flow in 5xFAD mice. *Contrast Media Mol Imaging* 2020;2020:8831936. doi: 10.1155/2020/8831936.
8. He Y, Wei M, Wu Y, et al. Amyloid beta oligomers suppress excitatory transmitter release via presynaptic depletion of phosphatidylinositol-4,5-bisphosphate. *Nature communications* 2019;10(1):1193.
9. Harraz OF, Longden TA, Hill-Eubanks D, Nelson MT. PIP<sub>2</sub> depletion promotes TRPV<sub>4</sub> channel activity in mouse brain capillary endothelial cells. *Elife* 2018;7. doi: 10.7554/eLife.38689.